Home
Resources
Publications
Drug-eluting Stents to Prevent Stent Thrombosis and Restenosis

Drug-eluting Stents to Prevent Stent Thrombosis and Restenosis

Eui Im, Myeong-Ki Hong

Expert Rev Cardiovasc Ther. 2016;14(1):87-104.

PMID: 26567863

Abstract:

Although first-generation drug-eluting stents (DES) have significantly reduced the risk of in-stent restenosis, they have also increased the long-term risk of stent thrombosis. This safety concern directly triggered the development of new generation DES, with innovations in stent platforms, polymers, and anti-proliferative drugs. Stent platform materials have evolved from stainless steel to cobalt or platinum-chromium alloys with an improved strut design. Drug-carrying polymers have become biocompatible or biodegradable and even polymer-free DES were introduced. New limus-family drugs (such as everolimus, zotarolimus or biolimus) were adopted to enhance stent performances. As a result, these new DES demonstrated superior vascular healing responses on intracoronary imaging studies and lower stent thrombotic events in actual patients. Recently, fully-bioresorbable stents (scaffolds) have been introduced, and expanding their applications. In this article, the important concepts and clinical results of new generation DES and bioresorbable scaffolds are described.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP221877549	Zotarolimus		221877-54-9	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: